BR9610836A - Composição antibacterial para administração oral - Google Patents

Composição antibacterial para administração oral

Info

Publication number
BR9610836A
BR9610836A BR9610836A BR9610836A BR9610836A BR 9610836 A BR9610836 A BR 9610836A BR 9610836 A BR9610836 A BR 9610836A BR 9610836 A BR9610836 A BR 9610836A BR 9610836 A BR9610836 A BR 9610836A
Authority
BR
Brazil
Prior art keywords
oral administration
antibacterial composition
antibacterial
composition
oral
Prior art date
Application number
BR9610836A
Other languages
English (en)
Inventor
Abe Kenichi
Ota Masato
Yamaguchi Hiroyuki
Murakami Chikako
Kikkoji Toshihiro
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of BR9610836A publication Critical patent/BR9610836A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2063Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9610836A 1995-10-13 1996-10-14 Composição antibacterial para administração oral BR9610836A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26584795 1995-10-13
PCT/JP1996/002967 WO1997013516A1 (en) 1995-10-13 1996-10-14 Antibacterial composition for oral administration

Publications (1)

Publication Number Publication Date
BR9610836A true BR9610836A (pt) 1999-07-13

Family

ID=17422903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610836A BR9610836A (pt) 1995-10-13 1996-10-14 Composição antibacterial para administração oral

Country Status (15)

Country Link
US (1) US5958915A (pt)
EP (1) EP0862915B1 (pt)
KR (1) KR100311576B1 (pt)
CN (1) CN1102046C (pt)
AR (1) AR004014A1 (pt)
AT (1) ATE214930T1 (pt)
BR (1) BR9610836A (pt)
CA (1) CA2234426C (pt)
DE (1) DE69620220T2 (pt)
ES (1) ES2174109T3 (pt)
HU (1) HU224922B1 (pt)
MX (1) MX9802849A (pt)
PT (1) PT862915E (pt)
TW (1) TW458778B (pt)
WO (1) WO1997013516A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736555B2 (en) * 1998-01-07 2001-08-02 Meiji Seika Pharma Co., Ltd. A composition comprising a crystallographically stable, amphorous cephalosporin and processes for the preparation thereof
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AU2002224053A1 (en) * 2000-11-21 2002-06-03 Kyorin Pharmaceutical Co. Ltd. Dry syrup preparations
WO2002043704A1 (fr) * 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition a solubilite ou absorbabilite orale amelioree
EP1401402B1 (en) 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
AUPS303202A0 (en) * 2002-06-20 2002-07-11 Pacific Biolink Pty Limited Protein based oral lubricant
EP1555024B1 (en) 2002-10-02 2010-09-29 Meiji Seika Kaisha Ltd. Antibacterial medicinal composition of enhanced oral absorptivity
PT1671635E (pt) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Composição de antibiótico amorfo contendo cefditoreno pivoxil
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
CN101115459B (zh) 2004-11-16 2012-03-21 3M创新有限公司 包括含磷表面处理的牙科填料
AU2005306857A1 (en) 2004-11-16 2006-05-26 3M Innovative Properties Company Dental compositions with calcium phosphorus releasing glass
KR101277869B1 (ko) 2004-11-16 2013-07-30 쓰리엠 이노베이티브 프로퍼티즈 컴파니 포스페이트 염을 포함하는 치과용 충전제 및 조성물
CN102342889A (zh) 2004-11-16 2012-02-08 3M创新有限公司 包括酪蛋白酸盐的牙科组合物及其应用
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
WO2010068359A1 (en) 2008-12-11 2010-06-17 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
WO2012010938A2 (en) * 2010-07-23 2012-01-26 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105663058A (zh) * 2016-02-01 2016-06-15 济南康和医药科技有限公司 一种头孢妥仑匹酯纳米粒药物制剂及制备方法
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936609A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS59184122A (ja) * 1983-03-31 1984-10-19 Nitto Electric Ind Co Ltd アクリル系膏体
JPS60102168A (ja) * 1983-11-08 1985-06-06 Tsukishima Shokuhin Kogyo Kk エイコサペンタエン酸強化乳化物及び食品の製造方法
IE58487B1 (en) * 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH0635394B2 (ja) * 1989-02-28 1994-05-11 雪印乳業株式会社 薬物の溶解性および吸収性の改善方法
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤

Also Published As

Publication number Publication date
EP0862915A4 (en) 1998-11-11
CN1202110A (zh) 1998-12-16
CA2234426A1 (en) 1997-04-17
EP0862915A1 (en) 1998-09-09
HUP9900609A3 (en) 2001-04-28
KR19990064137A (ko) 1999-07-26
DE69620220T2 (de) 2002-11-28
ATE214930T1 (de) 2002-04-15
US5958915A (en) 1999-09-28
AR004014A1 (es) 1998-09-30
KR100311576B1 (ko) 2001-12-28
ES2174109T3 (es) 2002-11-01
HK1016477A1 (en) 1999-11-05
WO1997013516A1 (en) 1997-04-17
TW458778B (en) 2001-10-11
MX9802849A (es) 1998-11-30
PT862915E (pt) 2002-09-30
DE69620220D1 (de) 2002-05-02
CA2234426C (en) 2003-07-08
EP0862915B1 (en) 2002-03-27
HUP9900609A2 (hu) 1999-07-28
HU224922B1 (en) 2006-04-28
CN1102046C (zh) 2003-02-26

Similar Documents

Publication Publication Date Title
PT862915E (pt) Composicao antibacteriana para administracao oral
PT812195E (pt) Composicao farmaceutica para compostos de piperidinoalcanol
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
NO20004345L (no) Farmasøytisk sammensetning
IS4706A (is) Lyfjasamsetningar
FI20071025L (fi) Farmaseuttisia koostumuksia
DK0936913T3 (da) Oralt farmaceutisk præparat indeholdende ibandronat
BR9508844A (pt) Composição oral
BR9506536A (pt) Composição oral
EP0836470A4 (en) ORAL COMPOSITIONS
PT868911E (pt) Formulacoes de rapamicina para administracao oral
BR9507768A (pt) Composição farmacêutica
FI973229A7 (fi) Uusi farmaseuttinen koostumus
LV11727A (lv) Farmaceitiska kompozicija
ID18698A (id) Komposisi farmasi
BR9607433A (pt) Composição farmacêutica para administração parental
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
BR9605777A (pt) Composição farmacêutica
ITMI962628A0 (it) Composizione farmaceutica
FI962738A7 (fi) Farmaseuttiset koostumukset
FI954050A7 (fi) Lääkekoostumuksia
NO964309D0 (no) Farmasöytisk sammensetning
ITMI950120A0 (it) Composizione farmaceutica contenente n-acetil-cisteina
SE9402925D0 (sv) Novel oral pharmaceutical composition
SE9402924D0 (sv) Novel pharmaceutical composition

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MEIJI SEIXA PHARMA CO., LTD (JP)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/10/2016